Evidence map›Paper›PMID 25990477›Full record

ArticleArchives of gynecology and obstetrics2015

Myo-inositol is a promising treatment for the prevention of ovarian hyperstimulation syndrome (OHSS): an animal study.

Guluzar Arzu Turan, Fatma Eskicioglu, Oya Nermin Sivrikoz, Hakan Cengiz, Saban Adakan, Esra Bahar Gur, Sumeyra Tatar, Nur Sahin, Osman Yilmaz

Erratum issuedOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of gynecology and obstetrics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Review
  7. Inositol and In Vitro Fertilization with Embryo Transfer.International journal of endocrinology · 2017
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Guluzar Arzu TuranDepartment of Obstetrics and Gynecology, Medical School, Sifa University, Sanayi cad no:7, 35100, Bornova, Izmir, Turkey. arzuturan74@yahoo.com.
Fatma EskiciogluDepartment of Obstetrics and Gynecology, Medical School, Celal Bayar University, 45030, Manisa, Turkey.
Oya Nermin SivrikozDepartment of Pathology, Medical School, Sifa University, Sanayi cad no:7, 35100, Bornova, Izmir, Turkey.
Hakan CengizBiostatistics and Medical Informatics, Medical School, Sifa University, Ankara Cad. No:45, 35100, Bayrakli, Izmir, Turkey.
Saban AdakanDepartment of Obstetrics and Gynecology, Medical School, Sifa University, Sanayi cad no:7, 35100, Bornova, Izmir, Turkey.
Esra Bahar GurDepartment of Obstetrics and Gynecology, Medical School, Sifa University, Sanayi cad no:7, 35100, Bornova, Izmir, Turkey.
Sumeyra TatarDepartment of Obstetrics and Gynecology, Medical School, Sifa University, Sanayi cad no:7, 35100, Bornova, Izmir, Turkey.
Nur SahinDepartment of Obstetrics and Gynecology, Medical School, Sifa University, Sanayi cad no:7, 35100, Bornova, Izmir, Turkey.
Osman YilmazDepartment of Laboratory Animal Science, Medical School, Dokuz Eylul University, Mithatpasa cad. No:1606 inciraltı yerleskesi, 35340, Balcova, Izmir, Turkey.
Şifa University · TRDokuz Eylül University · TRManisa Celal Bayar University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the efficacy of myo-inositol (MI) pretreatment in OHSS.

methodsIn this experimental OHSS rat model, 42 immature Wistar albino female rats were divided into 6 groups: (1) the control group, (2) the ovarian stimulation group, (3) the OHSS group, (4) the OHSS + Metformin group, (5) OHSS + MI group, (6) OHSS + Metformin + MI group. OHSS was established after treatment with metformin and myo-inositol for 14 days, in the meanwhile the treatment of metformin and myo-inositol was also continued. All animals were killed 48 h after hCG administration and were compared in terms of vascular permeability, ovarian weight and diameter, ovarian VEGF, COX-2 and PEDF expression (immunohistochemistry), serum PEDF and estradiol (E2) levels.

resultsVascular permeability, VEGF and COX-2 expressions were reduced in animals treated with MI and/or metformin. While PEDF expression was increased in the groups taking metformin, there was no difference in PEDF expression in the group taking MI and OHSS group. There was no significant difference in serum PEDF levels between groups. Blood E2 levels were decreased in groups treated with MI or metformin compared to the OHSS group.

conclusionsOur data demonstrate that myo-inositol is effective in preventing OHSS, similar to metformin. Although the two drugs are thought to act through distinct mechanisms, there is no apparent benefit to co-treatment with both drugs in an animal model of OHSS. Administration of myo-inositol prior to IVF treatment may favor the control of ovulation induction. Further studies are necessary to elucidate the mechanism of action and further support our findings.

Indexed as

AnimalsCyclooxygenase 1Disease Models, AnimalEstradiolFemaleInositolMembrane ProteinsOvarian Hyperstimulation SyndromeOvulation InductionRatsRats, WistarVascular Endothelial Growth Factor AVitamin B ComplexCyclooxygenase 1EstradiolInositolMembrane ProteinsPtgs1 protein, ratVascular Endothelial Growth Factor AVitamin B ComplexMetforminMyo-inositolOvarian hyperstimulation syndromePigment epithelium-derived factorVascular endothelial growth factor

Identifiers

PMID25990477
PMCPMC4723627
OpenAlexW250095143

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.